Vitamin D deficiency in prostate cancer: Prevalence in a sun-rich climate and influence of androgen deprivation therapy

Figure 1 Vitamin D deficiency prevalence rates by prostate cancer stage, with the highest prevalence observed in metastatic castration-resistant prostate cancer. mCSPC: Metastatic castration-sensitive prostate cancer; mCRPC: Metastatic castration-resistant prostate cancer.

Figure 2  Vitamin D deficiency prevalence rates by race, showing the highest prevalence in Black and Hispanic patients.

Figure 3 Comparison of pre- and post-androgen deprivation therapy vitamin D levels, showing no significant change across different groups. ADT: Androgen deprivation therapy.